Highlights for α-fetoprotein in determining prognosis and treatment monitoring for hepatocellular carcinoma

Table 1 Main characteristics and results of eligible studies

Author	Year	Country	OS		PFS		Overall response rate	Disease control rate
			Univariate analysis	Multivariate analysis	Univariate analysis	Multivariate analysis
Chen et al[21]	2005	China	S	S	N/A	N/A	N/A	N/A
Chan et al[20]	2009	China	S	S	N/A	N/A	P	P
Riaz et al[27]	2009	United States	S	S	N/A	N/A	P	P
Vora et al[29]	2009	United States	N/A	NS	N/A	NS	P	P
Shao et al[28]	2010	China	N/A	S	N/A	S	P	P
Kim et al[23]	2011	South Korea	S	S	S	S	P	P
Yau et al[30]	2011	China	S	S	S	S	N/A	N/A
Kao et al[22]	2012	China	N/A	S	N/A	N/A	N/A	N/A
Lee et al[24]	2012/H	South Korea	S	S	S	NS	P	P
Lee et al[24]	2012/C	South Korea	S	S	S	NS	P	P
Memon et al[25]	2012	United States	S	S	N/A	N/A	C	N/A
Personeni et al[26]	2012	Italy	N/A	S	N/A	N/A	N/A	N/A

2012/H: Hepatic arterial infusional chemotherapy study; 2012/C: Concurrent chemoradiation therapy study; S: Significant relationship between α-fetoprotein (AFP) response and survival; NS: No significant relationship between AFP response and survival; N/A: Not available or not applicable; P: Directly provided by the article; C: Need to be calculated by the data provided by the article; OS: Overall survival; PFS: Progression-free survival.